intermediate risk Myelofibrosis (DBCOND0023486)

Identifiers

Synonyms

Not Available

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Momelotinib	A Janus Kinase inhibitor used to treat intermediate or high-risk myelofibrosis.	Cytochrome P450 3A4enzyme Cytochrome P450 2C8enzyme Cytochrome P450 2C9enzyme Cytochrome P450 2C19enzyme Cytochrome P450 1A2enzyme Cytochrome P450 2B6enzyme UDP-glucuronosyltransferase 1A1enzyme UDP-glucuronosyltransferase 1A9enzyme ATP-dependent translocase ABCB1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Solute carrier organic anion transporter family member 1B1transporter Solute carrier organic anion transporter family member 1B3transporter Tyrosine-protein kinase JAK1target Tyrosine-protein kinase JAK2target Tyrosine-protein kinase JAK3target Non-receptor tyrosine-protein kinase TYK2target Activin receptor type-1target Receptor-type tyrosine-protein kinase FLT3target
Ruxolitinib	A kinase inhibitor used to treat various types of myelofibrosis, polycythemia vera in patients who have not responded to or cannot tolerate hydroxyurea, and to treat graft-versus-host disease in cases that are refractory to steroid treatment.	Tyrosine-protein kinase JAK1target Tyrosine-protein kinase JAK2target Cytochrome P450 3A4enzyme Cytochrome P450 2C9enzyme Albumincarrier Tyrosine-protein kinase JAK3target Non-receptor tyrosine-protein kinase TYK2target Urokinase plasminogen activator surface receptortarget

Clinical Trials

Not Available